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The incidence of malignant tumors in renal allograft recipients is higher than in the general population. Kidney carcinomas 
represent 4.8% of the tumors in transplant patients. Only 10% of them occur in the transplanted kidney. Graft tumors can 
be transmitted by donors, metastases from the recipient’s native organs, or de novo development after transplantation. The 
mean time to diagnosis of the tumor after transplantation is 10 years. We report the case of a 45-year old male patient with an 
incidental locally confined 15 mm renal cell carcinoma detected in allograft kidney’s lower pole 16 years after the transplanta-
tion. The patient successfully underwent a minimally invasive procedure - percutaneous radiofrequency ablation, completely 
eliminating the tumor and preserving graft function with no signs of early complications. One year after the procedure, there 
is no evidence of oncological disease recurrence or late complications and the patient maintains an adequate graft function 
with no need for hemodialysis.
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Pastebėta, jog piktybinių navikų dažnis žmonėms, kuriems persodinti inkstai, yra didesnis nei bendrojoje populiacijoje. Inkstų 
karcinomos sudaro 4,8 % visų navikų, nustatomų recipientams, ir vos 10 % – transplantate. Transplantato navikai gali būti perduoti 
donoro, metastazės iš kitų recipiento organų arba de novo (naujai) vystytis po transplantacijos. De novo navikai transplantate 
nustatomi vidutiniškai 10 metų po transplantacijos. Mes aprašome klinikinį atvejį 45 metų vyro, kuriam 16 metų po inksto per-
sodinimo atsitiktinai aptikta besimptomė neišplitusi 15 mm dydžio papilinė inksto karcinoma apatiniame transplantato poliuje. 
Ligoniui sėkmingai atlikta minimaliai invazyvi procedūra – perkutaninė radiodažninė abliacija, kuri visiškai sunaikino naviką 
išsaugodama transplantato funkciją. Ankstyvųjų komplikacijų nenustatyta. Praėjus vieneriems metams po procedūros vėžinės 
ligos atsinaujinimo ar vėlyvųjų komplikacijų požymių nėra, išlieka adekvati transplantato funkcija be hemodializės poreikio.
Reikšminiai žodžiai:  de novo transplantato navikas, perkutaninė radiodažninė abliacija, inkstų karcinoma.
Introduction
Kidney transplantation still remains the best treatment 
choice for patients with end-stage renal disease taking 
into account the survival and quality of life. However, 
it is estimated, that in about 6% of transplant recipients 
some kind of neoplasm will develop, mostly skin ma-
lignancies and non-Hodgkin lymphomas [1, 2]. Kidney 
carcinomas represent 4.8% of post-transplant cancers, 
as compared with 2.3% of tumors in the general popu-
lation. However, among these carcinomas, only 10% 
occur in kidney grafts [3, 4]. Graft tumors can be trans-
mitted by donors, metastases from the recipient’s native 
organs, or de novo development after transplantation [5]. 
An increase in the detection of mostly incidental tumors 
in renal transplants is associated with the increasing 
use of transplants from elderly donors and long-term 
immunosuppression [6]. Moreover, monitoring alone 
(regular ultrasound screening) can enhance the number 
of incidental tumors detected [6, 7].  The mean time to 
diagnosis of the tumor after transplantation is 10 years, 
although, in our case, it took 16 years [7]. Radical and 
nephron-sparing nephrectomies have been the treat-
ments of choice for transplant patients for a long time 
but percutaneous ablative therapy, which is minimally 
invasive procedure with lower morbidity, is now conside-
red as a well-established therapeutic approach and taking 
its place in treatment algorithms [8]. Due to the rarity of 
allograft kidney tumors and very few articles involving 
treatment with percutaneous thermal ablation, our aim 
is to share our experience and short-term results.
Clinical case presentation
We present the case of a 45-year old male patient with 
medical history of arterial hypertension, gastric ul-
cers and an end-stage renal disease caused by chronic 
glomerulonephritis. In 1998, the patient received a 
kidney transplant from a live donor (his brother) in 
the right iliac fossa. Maintenance immunosuppressive 
therapy included Methylprednisolone, Azathioprine 
and Cyclosporine. In 2009, a routine ultrasound sho-
wed 1st grade hydronephrosis, which progressed. A 
computer tomography (CT) scan was carried out but 
no clear cause of hydronephrosis or any lesions were 
identified at that time. The kidney graft function was 
limited: glomerular filtration rate 30 (ml/min/1.73 m2), 
and creatinine levels stable in an 18-month period 
(221→198→264→222 µmol/l).  In September 2014, 
a CT scan (without contrast since the serum creatinine 
level was high) detected a pyeloureteral stricture and a 
solid ~15 mm lesion in the transplant kidney’s lower 
pole parenchyma. It should be noted that the lesion 
had no influence to the nephrostasis and was incidental. 
By revising the prior CT scans made in 2009, a smaller 
lesion in the same location that had not been reported 
earlier was detected. The tumor was slowly growing 
from <10 mm to ~15 mm in a 5 years’ period. After 
the needle biopsy, primary results showed xanthogra-
nulomatous pyelonephritis and nephrosclerosis. It was 
decided to perform pyeloplasty and ureter stenting to 
eliminate the cause of hydronephrosis (pyeloureteral 
stricture) and preserve the graft kidney function. The 
further treatment tactics were planned to be discussed 
after the final histology results. The final biopsy results 
confirmed the disease corresponded to papillary carcino-
ma (G3, grade 3 Fuhrman). Taking into consideration 
eligible tumor size (TNM T1a), location, graft function 
and available equipment, a minimally invasive procedu-
re would have been the best choice of treatment. Thus it 
was proposed to carry out percutaneous radiofrequency 
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ablation therapy (RFA). RFA with intraoperative ultra-
sound targeting was performed in October 2014. Graft’s 
lower pole ~13 mm solid tumor was destructed using 
two T20 (15 cm) needles, 40W power, 30 KJ energy (in 
66 minutes). Prophylactic antibiotics were prescribed 
before and after the procedure. The patient was released 
from the hospital 3 days after the operation with no 
complications and adequate renal function. CT scan 
control after 2, 6 and 12 months detected no evidence 
of disease recurrence or late complications. The patient 
maintained an adequate allograft function with no need 
for hemodialysis. 
Discussion
Transplant patients must stay on immunosuppressive 
therapy, therefore, they gain a higher risk of developing 
some kind of neoplasm. The risk of renal cell carcinoma 
(RCC) is two times bigger in transplant patients than in 
general population [3]. The incidence of de novo carci-
noma in kidney allografts is reported to be 0.19–0.5% 
[8, 9]. Graft tumors can be transmitted by donors, 
metastases from the recipient’s native organs, or de novo 
development after transplantation [5]. Penn considered 
kidney graft tumors detected within 2 years after the 
transplantation to be most likely transmitted [4]. Ho-
wever, the reported time between the transplantation 
and the development of de novo RCC in transplanted 
kidneys is ranging from 9 months to 27 years [7, 11]. 
Based on Tillou et al. exhaustive literature review, the 
mean time to diagnosis of the tumor after transplanta-
tion is 126.2 ± 69.8 months [7]. The estimated growth 
of these tumors is between 5 and 10 mm per year, thus 
identical to the tumors found in native kidneys and in 
patients without transplants [12]. In our case, the tumor 
is diagnosed 16 years after the transplantation, although, 
a small lesion was detected revising CT scans made in 
2009. Comparing CT scans done in 2009 and 2014, the 
tumor size enlarged only ~1 cm in 5 years.
The diagnosis of a graft kidney malignancy is typically 
incidental, usually during the regular follow-up ima-
ging. The diagnosis is made using abdominal ultrasound 
or a CT scan. Similar to native kidney tumors, sympto-
matic kidney graft tumors have a worse prognosis [13]. 
Cornelis et al. found that renal papillary carcinoma 
accounted for 85% of the histologic subtypes found in 
Figure 1. A – CT scan before RFA, B – CT scan 6 months 
after RFA, C – CT scan 12 months after RFA
A
B
C
transplant patients, compared with the 10%–15% of 
these subtypes encountered in the general population [6, 
12]. According to Gelb, this type of tumor has a better 
prognosis in comparison to clear cell carcinoma [14]. 
Papillary carcinoma represented 55.7% of the tumors 
in the Tillou et al. study (2012) [9], although the later 
systematic review revealed the most common tumor was 
clear cell carcinoma (46.4% versus 43.7%). Study found 
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an overall 79.1% of low-grade tumors (Grade 1 and 2 
of Fuhrman), therefore concluded that de novo graft 
tumors seemed to be predominantly low-grade and not 
aggressive [7].  In our case the tumor was a high-grade 
(G3, grade 3 Fuhrman) confined (TNM T1a) papillary 
carcinoma.
Renal transplant recipients with graft RCC present a 
dilemma: if a conservative approach was chosen to pre-
serve the graft, the patient would be placed at a greater 
risk of cancer progression due to immunosuppressant 
induced immune incompetence. Therefore, such tumors 
are approached surgically at the risk of losing the only 
functioning kidney. Transplantectomy is usually justi-
fied by symptomatic and >40 mm graft tumors (TNM 
T2 or higher) [7, 15]. Nephron sparing surgery (NSS) is 
recommended for graft kidney tumors ≤40 mm (TNM 
T1b) with an eccentric location and a good blood sup-
ply to the rest of the allograft parenchyma [9, 10, 16]. 
However, NSS is now recommended by the European 
Association of Urology guidelines for native kidney 
tumors >40 mm (TNM T1b) [7, 15]. NSS preserves 
graft functions and helps patients to avoid returning to 
dialysis that is associated with inferior life expectancy 
and quality of life. Nevertheless, NSS can appear tech-
nically difcult because it is performed in a non-naive 
surgical field making kidney mobilization, parenchymal 
resection and other manipulations complex [17].
The growth of interest in minimally invasive proce-
dures has been triggered by finding the relation between 
the number of functional nephrons left after the tumor 
resection and patient survival [18]. Two minimally 
invasive techniques used in <40 mm (TNM T1a) RCC 
treatment are RFA and cryoablation. RFA is perfectly 
suited in such cases as it only slightly reduces the num-
ber of nephrons (RFA 11% versus NSS 35%) and does 
not require intraoperative ischemia that might induce 
associated parenchymal injury [19]. Based on Regier 
and Chun systematic review, the primary technical 
success rate of RFA in non-transplant patients ranged 
from 88% to 100% with the complication rate from 1% 
to 7%. [20]. Cornelis et al. had 100% success rate with 
one complication in their 24 graft RCC patient group, 
which resembled to other studies [6]. Therefore, it can 
be assumed that the results in transplant and non-trans-
plant patients are similar. The few authors who reported 
their primary success rates after cryoablation found 
them somewhat higher compared to RFA. Moreover, 
the result of the ablation can be instantly visualised 
with ultrasound control during the intervention as a 
hypodense ice ball. However, there are no randomized 
controlled trials comparing the two techniques [20]. In 
the present case, the tumor in a graft kidney with limi-
ted function was successfully treated with RFA with no 
cancer progression after 12 months as verified by CT.
Conclusions
Percutaneous radiofrequency ablation therapy is a fea-
sible option for patients with small (TNM T1a) kidney 
graft tumors or in such cases, when the patient is not eli-
gible for surgery (surgery refusal, old age or other treated 
cancers). Due to minimal invasiveness, high success rate, 
low complication rate, low mortality and short hospital 
stay, percutaneous radiofrequency ablation technique 
is an important addition to the selection of effective 
treatments for locally confined renal tumors, especially 
in functioning allografts.
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